

inhibitor, wherein said optimal composition contains said IMPDH inhibitor in an amount such that a ratio of Cavg/Cmin is between 1 to 10;

wherein:

Cavg is average plasma concentration produced by said IMPDH inhibitor in said human; and

Cmin is estimated trough concentration produced by said IMPDH inhibitor in said human.

5. (Amended) The method according to any of claims 2-4, wherein said ratio is between 1-8.

8. (Amended) The method according to claim 7, wherein said IMPDH inhibitor is selected from mycophenolic acid, ribavirin, VX-497, VX-148 or VX-944.

11. (Amended) The method according to claim 9, wherein said IMPDH inhibitor is VX-497.

12. (Amended) The method according to claim 9, wherein said IMPDH inhibitor is mycophenolic acid.

REMARKS

THE AMENDMENTS

Applicant's have amended the specification to capitalize and add the proper generic terminology to the trademarks CELLCEPT®, INTRON A®, PEGINTRON®, PEGASYS®, and REBETRON®.